ANTX — AN2 Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $36.72m
- -$46.90m
- 18
- 50
- 76
- 46
Annual balance sheet for AN2 Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS/A | PROSPECTUS/A | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 4.07 | 58.6 | 96.1 | 107 | 83.6 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 4.23 | 60.1 | 98.6 | 111 | 86.3 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 4.23 | 65.3 | 103 | 139 | 92.1 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1.46 | 3.4 | 7.19 | 14 | 10.2 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 1.48 | 3.41 | 7.19 | 14 | 10.2 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 2.75 | 61.9 | 95.4 | 125 | 81.8 |
| Total Liabilities & Shareholders' Equity | 4.23 | 65.3 | 103 | 139 | 92.1 |
| Total Common Shares Outstanding |